These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 33143687)

  • 1. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.
    Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
    Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping of the EORTC QLQ-C30 to EQ-5D-5L index in patients with lymphomas.
    Xu RH; Wong ELY; Jin J; Dou Y; Dong D
    Eur J Health Econ; 2020 Dec; 21(9):1363-1373. PubMed ID: 32960388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores.
    Meunier A; Soare A; Chevrou-Severac H; Myren KJ; Murata T; Longworth L
    Appl Health Econ Health Policy; 2022 Jan; 20(1):119-131. PubMed ID: 34554442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
    Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
    Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients.
    Kim SH; Jo MW; Kim HJ; Ahn JH
    Health Qual Life Outcomes; 2012 Dec; 10():151. PubMed ID: 23244763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping EORTC-QLQ-C30 onto EQ-5D-5L Index in Indonesian Cancer Patients.
    Perwitasari DA; Purba FD; Candradewi SF; Marwin M; Permata A; Ulfa Faza MB; Septiantoro BP; Kaptein AA
    Asian Pac J Cancer Prev; 2023 Apr; 24(4):1125-1130. PubMed ID: 37116132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.
    Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
    J Gastrointest Cancer; 2020 Mar; 51(1):196-203. PubMed ID: 30977049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
    Liu T; Li S; Wang M; Sun Q; Chen G
    Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
    Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
    Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancer.
    Noel CW; Stephens RF; Su JS; Xu W; Krahn M; Monteiro E; Goldstein DP; Giuliani M; Hansen AR; de Almeida JR
    Head Neck; 2020 Sep; 42(9):2277-2286. PubMed ID: 32333829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
    Lamu AN; Olsen JA
    Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France.
    Wojciechowski P; Wdowiak M; Hakimi Z; Wilson K; Fishman J; Nazir J; Toumi M
    J Comp Eff Res; 2023 May; 12(5):e220178. PubMed ID: 37052120
    [No Abstract]   [Full Text] [Related]  

  • 13. Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma.
    Arnold DT; Rowen D; Versteegh MM; Morley A; Hooper CE; Maskell NA
    Health Qual Life Outcomes; 2015 Jan; 13():6. PubMed ID: 25613110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms.
    Woodcock F; Doble B;
    Med Decis Making; 2018 Nov; 38(8):954-967. PubMed ID: 30226101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
    Proskorovsky I; Lewis P; Williams CD; Jordan K; Kyriakou C; Ishak J; Davies FE
    Health Qual Life Outcomes; 2014 Mar; 12():35. PubMed ID: 24618388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
    Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
    Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
    J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping Functions in Health-Related Quality of Life: Mapping from Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L.
    Young TA; Mukuria C; Rowen D; Brazier JE; Longworth L
    Med Decis Making; 2015 Oct; 35(7):912-26. PubMed ID: 25997920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients.
    Kim EJ; Ko SK; Kang HY
    Qual Life Res; 2012 Sep; 21(7):1193-203. PubMed ID: 22012023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
    Doble B; Lorgelly P
    Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.